Other biomarkers of interest in HF, such as Gal-3, endothelin and amylase, have shown a limited ability to discriminate between HF and non-HF patients, while cortisol, endothelin, UA, 8-isoPGFα, 8-epiPGFα, lactate and electrolytes have shown a limited ability to assess changes in clinical progression of HF patients. This evidence concerns the gene LGALS3 and hydrops fetalis.